202 related articles for article (PubMed ID: 22530561)
1. Formulation factors affecting the release of ezetimibe from different liquisolid compacts.
Khanfar M; Sheikh Salem M; Hawari R
Pharm Dev Technol; 2013; 18(2):417-27. PubMed ID: 22530561
[TBL] [Abstract][Full Text] [Related]
2. Liquisolid technique to enhance and to sustain griseofulvin dissolution: effect of choice of non-volatile liquid vehicles.
Elkordy AA; Essa EA; Dhuppad S; Jammigumpula P
Int J Pharm; 2012 Sep; 434(1-2):122-32. PubMed ID: 22677418
[TBL] [Abstract][Full Text] [Related]
3. Suitability of various excipients as carrier and coating materials for liquisolid compacts.
Hentzschel CM; Sakmann A; Leopold CS
Drug Dev Ind Pharm; 2011 Oct; 37(10):1200-7. PubMed ID: 21449826
[TBL] [Abstract][Full Text] [Related]
4. Influence of formulation parameters on dissolution rate enhancement of glyburide using liquisolid technique.
Singh SK; Srinivasan KK; Gowthamarajan K; Prakash D; Gaikwad NB; Singare DS
Drug Dev Ind Pharm; 2012 Aug; 38(8):961-70. PubMed ID: 22251080
[TBL] [Abstract][Full Text] [Related]
5. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts.
Nokhodchi A; Javadzadeh Y; Siahi-Shadbad MR; Barzegar-Jalali M
J Pharm Pharm Sci; 2005 Jan; 8(1):18-25. PubMed ID: 15946594
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of griseofulvin release from liquisolid compacts.
Hentzschel CM; Alnaief M; Smirnova I; Sakmann A; Leopold CS
Eur J Pharm Biopharm; 2012 Jan; 80(1):130-5. PubMed ID: 21846502
[TBL] [Abstract][Full Text] [Related]
7. In vitro release evaluation of hydrocortisone liquisolid tablets.
Spireas S; Sadu S; Grover R
J Pharm Sci; 1998 Jul; 87(7):867-72. PubMed ID: 9649356
[TBL] [Abstract][Full Text] [Related]
8. Spironolactone release from liquisolid formulations prepared with Capryol™ 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles.
Elkordy AA; Tan XN; Essa EA
Eur J Pharm Biopharm; 2013 Feb; 83(2):203-23. PubMed ID: 22960707
[TBL] [Abstract][Full Text] [Related]
9. Preparation of sustained-release dosage form of Venlafaxine HCl using liquisolid technique.
Khanfar M; Sheikh Salem M; Kaddour F
Pharm Dev Technol; 2014 Feb; 19(1):103-15. PubMed ID: 23347382
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation.
Fahmy RH; Kassem MA
Eur J Pharm Biopharm; 2008 Aug; 69(3):993-1003. PubMed ID: 18396390
[TBL] [Abstract][Full Text] [Related]
11. Effects of liquisolid formulations on dissolution of naproxen.
Tiong N; Elkordy AA
Eur J Pharm Biopharm; 2009 Nov; 73(3):373-84. PubMed ID: 19679184
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of dissolution rate of piroxicam using liquisolid compacts.
Javadzadeh Y; Siahi-Shadbad MR; Barzegar-Jalali M; Nokhodchi A
Farmaco; 2005 Apr; 60(4):361-5. PubMed ID: 15848213
[TBL] [Abstract][Full Text] [Related]
13. Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices.
Javadzadeh Y; Musaalrezaei L; Nokhodchi A
Int J Pharm; 2008 Oct; 362(1-2):102-8. PubMed ID: 18647643
[TBL] [Abstract][Full Text] [Related]
14. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine).
Javadzadeh Y; Jafari-Navimipour B; Nokhodchi A
Int J Pharm; 2007 Aug; 341(1-2):26-34. PubMed ID: 17498898
[TBL] [Abstract][Full Text] [Related]
15. [Liquisolid technique for enhancement of dissolution prosperities of tanshinone II(A)].
Liu XQ; Meng QJ; Xu XL; Zhao J; Yang H; Yi H
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4840-6. PubMed ID: 27245032
[TBL] [Abstract][Full Text] [Related]
16. Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design.
Naureen F; Shah Y; Shah SI; Abbas M; Rehman IU; Muhammad S; Hamdullah H; Goh KW; Khuda F; Khan A; Chan SY; Mushtaq M; Ming LC
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807252
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of ketoconazole dissolution rate by the liquisolid technique.
Molaei MA; Osouli-Bostanabad K; Adibkia K; Shokri J; Asnaashari S; Javadzadeh Y
Acta Pharm; 2018 Sep; 68(3):325-336. PubMed ID: 31259692
[TBL] [Abstract][Full Text] [Related]
18. Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties.
Javadzadeh Y; Siahi MR; Asnaashari S; Nokhodchi A
Acta Pharm; 2007 Mar; 57(1):99-109. PubMed ID: 19839410
[TBL] [Abstract][Full Text] [Related]
19. Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts.
Spireas S; Wang T; Grover R
Drug Dev Ind Pharm; 1999 Feb; 25(2):163-8. PubMed ID: 10065349
[TBL] [Abstract][Full Text] [Related]
20. Liquisolid compacts: the effect of cosolvent and HPMC on theophylline release.
Nokhodchi A; Aliakbar R; Desai S; Javadzadeh Y
Colloids Surf B Biointerfaces; 2010 Aug; 79(1):262-9. PubMed ID: 20451361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
